All market verdicts

NTLA UP market verdict | Ezbrisk

Published: 1786056103109

Anomaly score: 3.403220905499834

Confidence: 0.75

Market summary

Gene editing stock rallies violently on clinical progress

Ezbrisk assessment

Intellia's Q2 filing confirmed a widening loss to $106.6 million, but the stock moved violently higher as management highlighted Lonvo-z advancing toward a BLA filing, signaling tangible progress in their lead gene editing program despite the financial burn.

Sources: https://www.sec.gov/Archives/edgar/data/1652130/000119312526337952/ntla-20260630.htm

Verdict ID: 083a83c0-7ad3-40fa-b948-b2fe46dad7ac